Clearly, additional studies are needed, however, we strongly support determination of HIF-1-α expression by immunohistochemistry in serous ovarian cancer for devising subgroups for individualized treatment regimens. The gene discussed is HIF1A; the disease is ovarian serous adenocarcinoma.